RecruitingPhase 1NCT06343805
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ajax Therapeutics, Inc.
- Principal Investigator
- John Mascarenhas, M.D., MDMt. Sinai
- Intervention
- AJ1-11095(drug)
- Enrollment
- 76 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (16)
- Stanford Cancer Institute, Palo Alto, California, United States
- Moffitt Cancer Cancer Center, Tampa, Florida, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering, New York, New York, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Levine Cancer Institute, Charlotte, North Carolina, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- AP-HP Hopital Saint-Louis, Paris, France
- Hospital Clinic Barcelona, Barcelona, Spain
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06343805 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06327100Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)M.D. Anderson Cancer Center